- at Global HIMSS1 At the conference, Roche will introduce the navify Algorithm Suite. It is a single platform that enables clinicians to access medical algorithms to generate insights that help improve care decisions.
- The navify Algorithm Suite is a secure digital ecosystem that allows physicians to easily connect to a range of healthcare algorithms from Roche and its innovation partners without the hurdles of integrating multiple algorithm providers.
- The first available medical algorithms focus on identifying patients at risk for some liver and colon cancers. Medical algorithms for heart, lung, and other disease states are in the pipeline.
rottkreuz, Switzerland, April 11, 2023 /PRNewswire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) I’d like to introduce. Navify® The Algorithm Suite is a single platform that hosts a library of digital medical algorithms that can generate patient-centric insights and aid in early diagnosis of cancer and other conditions by intended use. HIMSS global conference in Chicago, united states of americafrom April 17-212023.
Roche
Physicians use medical algorithms, evidence-based decision-making tools, to diagnose, treat, and monitor patients to optimize care, increase early diagnosis, and adhere to guidelines. The use of real-time clinical decision support is associated with adherence to evidence-based guidelines and aids colorectal cancer screening.2,3
“As medical data grows,Four Digital medical algorithms can generate actionable insights that doctors can use to deliver on personalized healthcare promises. ” Moritz Hartmann, Global Head of Roche Information Solutions for Roche Diagnostics. “With the navify Algorithm Suite, clinicians can easily order the medical algorithms they need from Roche and other providers to gain enhanced insights that improve patient care.”
to navigate The Algorithm Suite provides labs and hospitals with one platform to easily connect to digital medical algorithms from various innovators. This makes it easy for doctors to use and adopt the medical algorithms they need. at the same time, to navigate The Algorithm Suite also provides universities and other providers of digital algorithms with a direct channel to distribute their proven innovations to practitioners in markets around the world.
The platform is designed to be integrated into existing healthcare workflows, laboratory or hospital information systems (LIS/HIS) and/or EHR/EMR (electronic health/medical records). Designed for optimal information security management, to navigate Algorithm Suite complies with GDPR (General Data Protection Regulation) regulations. Europe As with HIPAA (Health Insurance Portability and Accountability), united states of america.
first algorithm to navigate Algorithm suite focused on oncology:
- guardFive It is intended to aid in the diagnosis of early hepatocellular carcinoma (HCC) in patients with chronic liver disease. GAAD (In Vitro Diagnostic Multivariate Index Assay) analyzes gender, age in combination with the results of two Roche assays Elecsys AFP and Elecsys PIVKA.Algorithm for this CE mark6 It may help doctors diagnose early stage hepatocellular carcinoma (HCC).Liver cancer is his sixth most common cancer in the world7 HCC is the most common liver cancer, accounting for approximately 90% of cases.8 Not available in the US.
- A pre-screening algorithm to identify healthy individuals at risk for colorectal cancer. Medial EarlySign’s ColonFlag algorithm helps identify patients at high risk for colon cancer by analyzing age, gender, and recent complete blood count (CBC).9 Colorectal cancer is the third most common cancer in the world, with more than 1.9 million new cases of colorectal cancer in 2020.Ten In the US, the ColonFlag algorithm is marketed as LGI-Flag™ as an indicator of lower gastrointestinal disorders.
Additional algorithms for oncology, cardiology, and other diseases such as pulmonary and infectious diseases are already in the pipeline. to navigate The Algorithm Suite is now Europe and Asia Pacific.
Roche at HIMSS
information about to navigate The Algorithm Suite will be presented at the HIMSS Global Health Conference & Exhibition at the Roche booth (booth #6810). Chicago from April 17-21, 2023. Other key panels moderated by external speakers and Roche during HIMSS His discussions included:
- Accelerating access to innovation through an open ecosystem
- Digital innovation for better cancer care
- Accelerating the digital transformation of healthcare systems with digital infrastructure
- C-Suite: How to Influence Revenue in the Algorithm Ecosystem?
- Connected Learning Networks: The Next Frontier in Clinical Algorithm Validation?
The complete Roche HIMSS conference program is Available here.
About Navify
of to navigate Portfolio includes over 30 digital solutions11 For laboratories, hospitals and patients around the world. to navigate Digital solutions securely integrate data across diverse care environments, connect the healthcare community, and give clinicians access to the latest innovations and medical insights.Medical institutions can visit to navigate market Browse and request an ever-growing range of next-generation digital solutions from Roche and others. All of which are designed to promote operational and clinical excellence. See also the following URLs for more information: to navigate.com.
About Roche
Founded in 1896 Basel, SwitzerlandAs one of the first industrial manufacturers of branded pharmaceuticals, Roche has grown to become the world’s largest biotechnology company and a global leader in in vitro diagnostics. The company strives for scientific excellence to discover and develop medicines and diagnostics to improve and save lives around the world. We are pioneers in personalized healthcare and want to further transform the way healthcare is delivered to have an even greater impact. We partner with many stakeholders to combine the strengths of diagnostics and pharmaceuticals with data insights from clinical practice to provide the best possible care for each individual.
For the 13th consecutive year, Roche has been named one of the most sustainable companies in the pharmaceutical industry by the Dow Jones Sustainability Indices, in recognition of its efforts to pursue a long-term perspective in all that it does. The award also reflects our commitment to working with local partners to improve access to healthcare in all the countries in which we operate.
Genentech, usais a wholly owned subsidiary of the Roche Group. Roche is the largest shareholder of Chugai Pharmaceutical, Japan.
For more information, see: www.roche.com.
All trademarks used or mentioned in this release are protected by law.
References
|
1. |
Health Information Management Systems Society (HIMSS) |
|
|
2. |
American Journal of Managed Care.Choosing a Wise Clinical Decision Support Adherence and Related Inpatient Outcomes [Internet; cited 2018 Aug 15]Available from: Wise Choice Clinical Decision Support Adherence and Related Hospital Outcomes |
|
|
3. |
Collaboration to improve colorectal cancer screening using machine learning NEJM Catalyst Innovations in Care Delivery 2022; 04 roll. No. 3 No. 4 | | Published March 16, 2022 – April 2022 Daniel Underberger, MD, Keith Boell, DO, MS-HQSM, SFHM, Jeremy Orr, MD, MPH, Cory Siegrist, MBA, Sara Hunt https://catalyst. nejm.org/doi/full/10.1056/CAT.21.0170 |
|
|
Four. |
Reinsel D, Gantz J, Rydning J. Digitizing the world from the edge to the core. IDC White Paper – #US44413318. November 2018 |
|
|
Five. |
Elecsys GAAD is an in vitro diagnostic system intended to provide semi-quantitative results by algorithmically combining the quantitative measurements of the Elecsys AFP and Elecsys PIVKA-II assays in human serum and plasma with sex and age. A multivariate index assay for Elecsys GAAD is intended to aid in the diagnosis of early stage hepatocellular carcinoma (HCC). Elecsys GAAD is indicated for adults who meet the following criteria: Diagnosed with chronic liver disease and are at increased risk of developing HCC, and surveillance is recommended. The Elecsys GAAD should be interpreted in conjunction with other diagnostic findings and clinical information according to standard clinical management guidelines. |
|
|
6. |
GAAD is not registered in all countries. Please check the registration for each country. |
|
|
7. |
World Cancer Research Fund International.liver cancer statistics [Internet] Available from https://www.wcrf.org/cancer-trends/liver-cancer-statistics/ |
|
|
8. |
Nature Reviews Disease Primers.hepatocellular carcinoma [Internet; cited 2021 Jan 21] Available from https://www.nature.com/articles/s41572-020-00240-3 |
|
|
9. |
NEJM catalyst.Innovations from Care Delive, a collaboration to improve colorectal cancer screening using machine learningrye 2022; Vol. 04. No. 3 No. 4 [Internet; cited 2022 April] Available from: https://doi.org/10.1056/CAT.21.0170 and https://catalyst.nejm.org/doi/full/10.1056/CAT.21.0170 |
|
|
Ten. |
World Cancer Research Fund International.colon cancer statistics [Internet] Available from https://www.wcrf.org/cancer-trends/colorectal-cancer-statistics/ |
|
|
11. |
Digital solutions currently under cobas® infinity or Viewics will migrate over time to the navify brand and continue to provide the same value to healthcare organizations. |
|
Contact us for more information
Monica ReiserHead of Communications, Lab Insights, Roche Information Solutions
Phone: +41 79 909 4099
Email: [email protected]
christine englandHead of Communications, Provider Insights, Roche Information Solutions
Phone: +1 669 301 8709
Email: [email protected]
Jeric PalloneSenior Communications Manager, Roche Information Solutions
Phone: +41 794 383 797
Email: [email protected]
photograph – https://mma.prnewswire.com/media/2048610/Roche.jpg
Sauce Roche
